Driving Advances in Liver Health: Tackling Current Challenges in Viral Hepatitis and NASH

No therapies are FDA approved for NASH, but I believe metabolic, inflammatory, and fibrotic aspects of NASH will all shape its management.

Manal F. Abdelmalek, MD, MPH Released: October 4, 2019

Why the path to HCV elimination must reach PWID.

Oluwaseun Falade-Nwulia, MBBS, MPH Released: October 14, 2019

We must stay the course to eliminate HBV as a public health threat.

Paul Y. Kwo, MD
Program Director Released: October 16, 2019

How long should patients with chronic hepatitis B be treated with nucleos(t)ide analogues? When should we treat patients with immune-tolerant hepatitis B? Here’s my take.

Paul Y. Kwo, MD
Program Director Released: December 4, 2019

How can providers ensure that vulnerable populations are linked to HCV testing and care? Here’s my take on what we should be doing in our practice.

Oluwaseun Falade-Nwulia, MBBS, MPH Released: December 18, 2019

Here’s my take on bariatric surgery, noninvasive testing, and endpoints in patients with NASH.

Manal F. Abdelmalek, MD, MPH Released: January 16, 2020